CTSH vs. EPAM: Which Stock Is the Better Value Option?

A comparative analysis by Zacks Investment Research identifies Cognizant (CTSH) as a superior value opportunity over Epam (EPAM) within the IT Services sector. CTSH holds a Zacks Rank #2 (Buy) due to an improving earnings outlook, contrasting with EPAM's #3 (Hold) rank. Key valuation metrics, including forward P/E (CTSH 15.28 vs. EPAM 15.96), PEG (CTSH 1.77 vs. EPAM 1.79), and P/B (CTSH 2.57 vs. EPAM 2.73), contribute to CTSH receiving a 'B' Value grade compared to EPAM's 'C', positioning CTSH as the preferred option for value-focused investors.

Analysis

Based on a Zacks Investment Research comparative analysis, Cognizant (CTSH) presents a more compelling value proposition than Epam (EPAM) in the IT Services sector. The primary driver for this assessment is CTSH's superior Zacks Rank of #2 (Buy), which indicates a trend of positive earnings estimate revisions and an improving earnings outlook. This contrasts with EPAM's #3 (Hold) rank. On a quantitative valuation basis, CTSH consistently appears more attractive across several key metrics. Its forward P/E ratio of 15.28 is slightly lower than EPAM's 15.96, and its PEG ratio of 1.77 is marginally better than EPAM's 1.79, suggesting a better price relative to its growth forecast. Furthermore, CTSH's Price-to-Book (P/B) ratio of 2.57 is more favorable than EPAM's 2.73. This combination of superior valuation metrics culminates in CTSH earning a 'B' grade for Value, while EPAM receives a 'C', reinforcing the conclusion that Cognizant is the preferred value-oriented choice between the two at present.

Key Decisions for Investors

• Value-focused investors should consider Cognizant (CTSH) over Epam (EPAM) given its more attractive valuation multiples, including a lower forward P/E and P/B ratio, and its superior 'B' Value grade.
• Investors should note CTSH's #2 (Buy) Zacks Rank, which signals an improving earnings outlook and could be a catalyst for near-term stock performance.
• For those holding or considering Epam (EPAM), its #3 (Hold) rank and less attractive valuation metrics suggest a more cautious stance may be warranted until there is evidence of positive earnings estimate revisions or a more favorable entry point.